The
@FinancialTimes has run a piece highlighting UCLB spinout Autolus Therapeutics’ journey to produce therapies for cancer side effects 👏
The news story focuses on the work taking place at Autolus’ Stevenage facility, which is manufacturing the latest generation of an innovative, personalised cancer treatment: a new Car-T cell therapy to treat the blood cancer acute lymphoblastic leukaemia.
📖 Read more here: https://t.co/3IBqRtuZsL